Skip to main
BCYC

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 43%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics is a biopharmaceutical company with a strong focus on oncology and a promising product, zele, in its pipeline. The company has a current cash position that makes it well-equipped to fund its operations and continue advancing in clinical trials for zele. In addition, with potential partnerships and collaborations in the works, the company's BRC platform could hold valuable potential for future growth.

Bears say

Bicycle Therapeutics is facing challenges with its product development as evidenced by the discontinuation of two clinical trials and the decision to seek a potential partner for future development. Despite having a strong cash position as of YE25, the company has proposed a workforce reduction of approximately 30%, which may signify internal struggles. In addition, the company's competitive positioning may be weakened by potential superior efficacy and safety profiles of next-generation Nectin-4 ADCs with enhanced payloads. These challenges could limit the company's market share and pricing power and may result in dilution or alterations to its financing structures.

BCYC has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 43% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 7 analysts, BCYC has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.